Ang audio ng episode na ito ay maaaring sira.
How to fix it?
TUNGKOL SA EPISODE NA ITO
Listen to Tina Wang, Statistician, and Dr. Paul Schuette, Deputy Division Director, in the Office of Biostatistics Division of Analytics and Informatics within FDA’s Center for Drug Evaluation and Research discuss FDA’s experiences with a centralized statistical monitoring tool.
Ingles
Estados Unidos
I-SEARCH ANG MGA NAKARAANG EPISODE
I-search ang mga nakaraang episode ng FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
IBA PANG MGA EPISOD SA PODCAST NA ITO
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
Paunawa: Ang podcast at artwork na naka-embed sa page na ito ay mula sa U.S. Food and Drug Administration, Center for Drug Evaluation and Research, na pag-aari ng may-ari nito at hindi kaakibat o ineendorso ng Listen Notes, Inc.
I-EDIT
Salamat sa pagtulong na mapanatiling naka-update ang database ng podcast.
